Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Aurobindo Pharma Q2...

    Aurobindo Pharma Q2 net profit up by 5 pc to Rs 640 crore

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-14T09:30:12+05:30  |  Updated On 14 Aug 2021 11:37 AM IST

    Managing director of Aurobindo Pharma N Govindarajan said We had another quarter of healthy performance where we continued to grow in the US and Europe, which are our focused geographies. Our R&D (research and development) initiatives have been progressing well across the products basket and we have started clinical trials for our first biosimilar product in Q3 FY 20."


    Hyderabad: Aurobindo Pharma Limited on Tuesday said its consolidated net profit (after JV share, minority interest) for the quarter ended September 30 was up by 4.6 per cent to Rs 639.5 crore against Rs 611.4 crore in the Q2 FY 19.


    Revenue from operation grew by nearly 18 per cent to Rs 5600.5 crore. It was Rs 4,751.4 crore during the same period last fiscal, a company press release here said.


    Managing director of the firm N Govindarajan said We had another quarter of healthy performance where we continued to grow in the US and Europe, which are our focused geographies. Our R&D (research and development) initiatives have been progressing well across the products basket and we have started clinical trials for our first biosimilar product in Q3 FY 20."


    Read Also: Aurobindo Pharma USA recalls heartburn drug Ranitidine over cancer causing impurities


    Formulation revenues for the quarter posted a growth of 21.8 per cent YoY to Rs 4,793.8 crore and accounted for 85.6 per cent of total revenues, while EU formulations revenue in Q2 FY20 witnessed a growth of 21.2 per cent YoY to Rs 1,401.3 crore, the release said.


    The company filed 20 abbreviated new drug applications (ANDA) with USFDA including 2 injectables in Q2FY20.


    Read Also: Aurobindo Pharma gets 8 USFDA observations for 2 facilities in Hyderabad

    abbreviated new drug applicationsANDAAurobindo Pharmaaurobindo pharma financial resultsAurobindo pharma profitfiscal 2020FY20N Govindarajanpharmapharma newspharma news indiaQ3USFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok